Abbott Laboratories (ABT) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect almost 10% EPS growth over the next five years driven by strong sales of Humira and the company’s rapidly growing vascular business.
Several new drug applications have recently been filed with the FDA, which should accelerate sales in the pharmaceutical business. We believe ABT possesses a low risk profile and will continue to trade at an industry premium.
Accordingly, we reiterate our Buy recommendation with a price target of $65.Zacks Investment Research
